These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18338961)
1. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK; MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060 [TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ; J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358 [TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients. Casado A; Consiglio E; Podzamczer D; Badia X HIV Clin Trials; 2001; 2(6):477-83. PubMed ID: 11742436 [TBL] [Abstract][Full Text] [Related]
6. Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers. Castagna A; Danise A; Giudici B; Lazzarin A; Castelli F; Paraninfo G; Carosi G; Carriero PL J Chemother; 2002 Apr; 14(2):189-93. PubMed ID: 12017376 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. Sterling TR; Chaisson RE; Moore RD AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698 [TBL] [Abstract][Full Text] [Related]
8. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Aboulafia DM; Bundow D; Waide S; Bennet C; Kerr D Am J Med Sci; 2000 Aug; 320(2):117-23. PubMed ID: 10981487 [TBL] [Abstract][Full Text] [Related]
9. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study. Kim KH; Yi J; Lee SH Korean J Intern Med; 2015 Sep; 30(5):705-13. PubMed ID: 26354065 [TBL] [Abstract][Full Text] [Related]
10. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. Yamashita TE; Phair JP; Muñoz A; Margolick JB; Detels R; O'Brien SJ; Mellors JW; Wolinsky SM; Jacobson LP AIDS; 2001 Apr; 15(6):735-46. PubMed ID: 11371688 [TBL] [Abstract][Full Text] [Related]
11. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. Wutoh AK; Brown CM; Kumoji EK; Daftary MS; Jones T; Barnes NA; Powell NJ J Natl Med Assoc; 2001; 93(7-8):243-50. PubMed ID: 11491273 [TBL] [Abstract][Full Text] [Related]
12. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. Brigido LF; Rodrigues R; Casseb J; Oliveira D; Rossetti M; Menezes P; Duarte AJ AIDS Patient Care STDS; 2001 Nov; 15(11):587-93. PubMed ID: 11788069 [TBL] [Abstract][Full Text] [Related]
13. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. Laurent C; Diakhaté N; Gueye NF; Touré MA; Sow PS; Faye MA; Gueye M; Lanièce I; Touré Kane C; Liégeois F; Vergne L; Mboup S; Badiane S; Ndoye I; Delaporte E AIDS; 2002 Jul; 16(10):1363-70. PubMed ID: 12131213 [TBL] [Abstract][Full Text] [Related]
14. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Haubrich RH; Little SJ; Currier JS; Forthal DN; Kemper CA; Beall GN; Johnson D; Dubé MP; Hwang JY; McCutchan JA AIDS; 1999 Jun; 13(9):1099-107. PubMed ID: 10397541 [TBL] [Abstract][Full Text] [Related]
15. The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery. Michael CG; Kirk O; Mathiesen L; Nielsen SD Scand J Infect Dis; 2002; 34(1):45-9. PubMed ID: 11874164 [TBL] [Abstract][Full Text] [Related]
17. Decrease in immune activation in HIV-infected patients treated with highly active antiretroviral therapy correlates with the function of hematopoietic progenitor cells and the number of naive CD4+ cells. Nielsen SD; Sørensen TU; Ersbøll AK; Ngo N; Mathiesen L; Nielsen JO; Hansen JE Scand J Infect Dis; 2000; 32(6):597-603. PubMed ID: 11200367 [TBL] [Abstract][Full Text] [Related]
18. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. Pradier C; Carrieri P; Bentz L; Spire B; Dellamonica P; Moreau J; Moatti JP Int J STD AIDS; 2001 May; 12(5):324-8. PubMed ID: 11368807 [TBL] [Abstract][Full Text] [Related]
19. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. Frater AJ; Dunn DT; Beardall AJ; Ariyoshi K; Clarke JR; McClure MO; Weber JN AIDS; 2002 May; 16(8):1139-46. PubMed ID: 12004272 [TBL] [Abstract][Full Text] [Related]
20. Response to highly active antiretroviral therapy according to duration of HIV infection. Pezzotti P; Pappagallo M; Phillips AN; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G; J Acquir Immune Defic Syndr; 2001 Apr; 26(5):473-9. PubMed ID: 11391168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]